Reviewer's report

Title: Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection. I: analysis of cases.

Version: 1 Date: 5 April 2010

Reviewer: José Manuel Olivares

Reviewer's report:

The unexpected occurrence of a post-injection delirium/sedation syndrome (PIDS) in a number of patients that have received olanzapine long-acting injection in the pre-commercialization clinical trials will have important consequences in the real-world clinical practice. Clinicians will have to weigh the risk/benefit ratio of treatment with olanzapine LAI and will have to learn how to identify and manage this post-injection syndrome. This is why to publish all data available the PIDS is of the maximum interest.

I have reviewed the two papers: 'Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection. I: analysis of cases.' and "II: Investigations of mechanism". In both papers the question is well defined, the methods are appropriate, the data are sound, and the discussion and conclusions adequate to the data. However, I feel than the second paper (Investigations of mechanism) should be summarized as much as possible and be included into the first paper).

Level of interest: An article of importance in its field

Quality of written English: Acceptable

Statistical review: No, the manuscript does not need to be seen by a statistician.

Declaration of competing interests:

In the last five years, I have been member of regional, national, and international advisory boards for Janssen-Cilag, Lilly, Astra-Zeneca and Bristol-Myers. I have been involved in designing and participating in clinical trials for Janssen-Cilag, Lilly, Astra-Zeneca, Pfizer, Lundbeck, Glaxo and Bristol-Myers, and I have received educational grants for research, honoraria and travel support for activities as a consultant/advisor and lecturer/faculty member for Janssen-Cilag, Lilly, Astra-Zeneca, Pfizer, Lundbeck, Glaxo, Novartis and Bristol-Myers.